

KIMIABL/COMP/BSE/24-25/002

Date: 10.04.2024

To,  
Corporate Relationship Department  
BSE Limited  
P.J. Towers, 1<sup>st</sup> Floor, New Tradinzag Ring,  
Dalal Street, Mumbai- 400001

**Ref: BSE Scrip Code: 530313 and Scrip ID: KIMIABL**

**Sub:** Intimation under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 for written confirmation for active substances imported into the European Union (EU) for medical products for human use.

Dear Sir/ Madam,

The Company is pleased to inform that the Company has received the written confirmation for active substances imported into the European Union for medical products for human use, in accordance with Article 46(b)(2)(b) of Directives 2001/83/EC from Government of India, Ministry of Health & Family welfare, Central Drug Standard Control Organization vide Certificate no WC-0474.

The Company has received written confirmation of one product.

S. No	Active Substance	Activity
1.	Vildagliptin IH	Manufacturing & Packing

The said intimation is being given under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirement) Regulation 2015.

You are requested to take note of the above for your records.

Thanking you,  
Yours faithfully,  
For Kimia Biosciences Limited

  
**Lakshay Prakash**  
Compliance Officer & Company Secretary



**KIMIA BIOSCIENCES LIMITED**

Regd. Office/Works  
Village Bhondsi, Damdama Lake Road,  
Gurugram, Haryana -122102  
Tel.: +91 9654746544, 9654206544

**Corporate Office**  
974, 9<sup>th</sup> Floor, Aggarwal Millenium Tower-II  
Netaji Subhash Place, Pitampura, New Delhi-110034, INDIA  
Tel: +91 11 47063600, 470630601

compliance.kimia@gmail.com | info@kimiabiosciences.com | www.kimiabiosciences.com | CIN No.: L24239HR1993PLC032120